Thanks heaps for the poster data. How did you get it? Did it go...

Thanks heaps for the poster data. How did you get it? Did it go up after the presentation on Wednesday?

To be honest I was so discouraged by the lack of shareholder engagement here prior to the meeting that I nearly didn't send in my questions. Glad I did. Glad you did too. One of the questions on 3D sounded a bit like one of yours with the references to scale out or scale up from memory.

Wish I'd recorded the zoom meeting. I noted it was being recorded, but hadn't prep ed to record it myself. In my experience its worth taking a look at records again usually. I'd like to go through it again. So much information was in - for instance MSBs ODAC presentation that holders and most observers missed. In my opinion people almost rewrite their memories - we are just so biased to hearing what we expect (and usually what we want to hear).

I also think things are sometimes dropped in the details that companies don't appreciate the significant of - again I reference another company - Dr Rose's acknowledgement of problems with the potency assay in a webinar. Its never been acknowledged to my knowledge outside of that webinar yet it puts a lot of other things about MSB's potency assay and the FDA's comments into perspective that don't make sense otherwise, in my opinion.

I found Ross's responses to some of the questions I asked to be pretty good - (No to the mend milestones payment) Yes to the Fujifilm option (I made that yes or no to be brief - sometimes may doesn't also imply maybe not. You and I may obey the laws of physics - doesn't logically follow if someone uses that way of speaking that we may not).

I thought the approach to GvHD seemed sensible.

Ross's answer to the 3D prototyping (Q6) I found helped me understand his way of thinking - but I still think .... well a comment for another day.

Really interested in seeing the meeting again on zoom or elsewhere if that's doable?